News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,398 Results
Type
Article (40273)
Company Profile (251)
Press Release (668864)
Multimedia
Podcasts (67)
Webinars (15)
Section
Business (204401)
Career Advice (2014)
Deals (35469)
Drug Delivery (99)
Drug Development (81199)
Employer Resources (172)
FDA (16291)
Job Trends (14906)
News (345760)
Policy (32658)
Tag
Academia (2557)
Accelerated approval (14)
Adcomms (22)
Allergies (106)
Alliances (49572)
ALS (124)
Alzheimer's disease (1509)
Antibody-drug conjugate (ADC) (166)
Approvals (16335)
Artificial intelligence (349)
Autoimmune disease (38)
Automation (23)
Bankruptcy (361)
Best Places to Work (11635)
BIOSECURE Act (19)
Biosimilars (132)
Biotechnology (174)
Bladder cancer (111)
Brain cancer (39)
Breast cancer (407)
Cancer (3258)
Cardiovascular disease (263)
Career advice (1688)
Career pathing (32)
CAR-T (201)
CDC (34)
Cell therapy (540)
Cervical cancer (27)
Clinical research (67399)
Collaboration (1160)
Company closure (4)
Compensation (824)
Complete response letters (35)
COVID-19 (2657)
CRISPR (66)
C-suite (457)
Cystic fibrosis (119)
Data (3602)
Decentralized trials (2)
Denatured (22)
Depression (77)
Diabetes (376)
Diagnostics (6482)
Digital health (27)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (160)
Drug pricing (135)
Drug shortages (28)
Duchenne muscular dystrophy (168)
Earnings (88523)
Editorial (43)
Employer branding (21)
Employer resources (148)
Events (114563)
Executive appointments (885)
FDA (18392)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1032)
Gene editing (145)
Generative AI (24)
Gene therapy (422)
GLP-1 (827)
Government (4568)
Grass and pollen (5)
Guidances (330)
Healthcare (18851)
HIV (42)
Huntington's disease (31)
IgA nephropathy (47)
Immunology and inflammation (178)
Immuno-oncology (12)
Indications (44)
Infectious disease (2848)
Inflammatory bowel disease (161)
Inflation Reduction Act (10)
Influenza (76)
Intellectual property (152)
Interviews (313)
IPO (16604)
IRA (48)
Job creations (3639)
Job search strategy (1424)
Kidney cancer (13)
Labor market (63)
Layoffs (518)
Leadership (21)
Legal (7934)
Liver cancer (83)
Longevity (11)
Lung cancer (473)
Lymphoma (241)
Machine learning (21)
Management (58)
Manufacturing (487)
MASH (106)
Medical device (13552)
Medtech (13568)
Mergers & acquisitions (19664)
Metabolic disorders (926)
Multiple sclerosis (109)
NASH (16)
Neurodegenerative disease (150)
Neuropsychiatric disorders (36)
Neuroscience (2304)
NextGen: Class of 2025 (6517)
Non-profit (4492)
Now hiring (53)
Obesity (456)
Opinion (227)
Ovarian cancer (109)
Pain (135)
Pancreatic cancer (140)
Parkinson's disease (198)
Partnered (24)
Patents (359)
Patient recruitment (249)
Peanut (51)
People (57981)
Pharmaceutical (62)
Pharmacy benefit managers (21)
Phase I (20976)
Phase II (29686)
Phase III (22089)
Pipeline (2352)
Policy (226)
Postmarket research (2564)
Preclinical (8935)
Press Release (64)
Prostate cancer (159)
Psychedelics (39)
Radiopharmaceuticals (255)
Rare diseases (512)
Real estate (5926)
Recruiting (66)
Regulatory (23072)
Reports (51)
Research institute (2333)
Resumes & cover letters (350)
Rett syndrome (10)
RNA editing (11)
RSV (55)
Schizophrenia (104)
Series A (166)
Series B (128)
Service/supplier (11)
Sickle cell disease (68)
Special edition (19)
Spinal muscular atrophy (148)
Sponsored (34)
Startups (3595)
State (2)
Stomach cancer (14)
Supply chain (84)
Tariffs (71)
The Weekly (43)
Vaccines (857)
Venture capital (59)
Weight loss (281)
Women's health (51)
Worklife (17)
Date
Today (9)
Last 7 days (479)
Last 30 days (2018)
Last 365 days (30869)
2025 (21295)
2024 (35216)
2023 (40076)
2022 (51174)
2021 (55712)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (724)
Alabama (69)
Alaska (7)
Arizona (256)
Arkansas (13)
Asia (38432)
Australia (6267)
California (8471)
Canada (2621)
China (762)
Colorado (354)
Connecticut (360)
Delaware (222)
Europe (82705)
Florida (1266)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (677)
India (38)
Indiana (399)
Iowa (17)
Japan (256)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1124)
Massachusetts (6200)
Michigan (264)
Minnesota (503)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (97)
New Hampshire (68)
New Jersey (2317)
New Mexico (28)
New York (2305)
North Carolina (1176)
North Dakota (8)
Northern California (3840)
Ohio (259)
Oklahoma (16)
Oregon (35)
Pennsylvania (1793)
Puerto Rico (17)
Rhode Island (41)
South America (1098)
South Carolina (43)
South Dakota (1)
Southern California (3245)
Tennessee (138)
Texas (1302)
United States (30863)
Utah (251)
Virginia (209)
Washington D.C. (74)
Washington State (699)
West Virginia (4)
Wisconsin (71)
709,398 Results for "kempharm inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
KemPharm Issues Letter to Shareholders - January 24, 2023
KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.
January 24, 2023
·
12 min read
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm, Inc. announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”).
February 22, 2023
·
7 min read
Business
KemPharm Enhances Senior Management Team
KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.
January 31, 2023
·
4 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
Business
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.
November 29, 2022
·
6 min read
FDA
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.
November 18, 2022
·
6 min read
BioMidwest
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
KemPharm, Inc. announced changes to its Board of Directors and executive leadership team as part of the Company’s ongoing business transformation initiatives.
January 9, 2023
·
9 min read
Business
KemPharm announced its partnership with Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm, Inc. announced its partnership with the Hypersomnia Foundation , which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders.
January 18, 2023
·
8 min read
Business
KemPharm Reports Third Quarter 2022 Results
KemPharm, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, reported its financial results for the quarter ended September 30, 2022.
November 9, 2022
·
13 min read
Business
KemPharm to Report Third Quarter 2022 Financial Results
KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022.
November 1, 2022
·
2 min read
1 of 70,940
Next
